Older Patients With Schizophrenia: Challenges in the Coming Decades
Abstract
The number and proportion of older adults with schizophrenia will increase considerably in the coming decades. Although a vast literature on schizophrenia among younger adults exists, much less is known about late-life schizophrenia and its treatment. The authors describe two potential scenarios for 2011, the year that the first baby boomers will turn 65. To ensure that the more favorable scenario becomes a reality, the authors suggest four goals: decrease medical comorbidity and mortality among younger patients with schizophrenia and improve their access to health care so that they can live longer and more productive lives; improve our understanding of the neurobiological and psychosocial factors underlying late-life schizophrenia, as well as the health care and social service needs of such patients; develop more effective and safer pharmacologic, psychosocial, and cognitive behavioral treatments; and improve rehabilitation of older people with schizophrenia. Specific strategies to foster these goals include establishing a consortium for studies of late-life schizophrenia; conducting multicenter studies of treatment effectiveness; and forming interdisciplinary collaborations among researchers, clinicians, government and industry representatives, and patient advocacy groups.
Schizophrenia is often thought of as a disorder affecting adolescents and young adults, but the coming decades will bring about an unprecedented increase in the number and proportion of elderly Americans with this disorder. The first members of the baby-boom generation turn 65 in the year 2011, which will begin a rapid increase in the number of elderly persons within the general population (1). Also, development of additional treatment options may reduce mortality from this disorder. For example, up to 13 percent of people with schizophrenia commit suicide (2), but treatment with clozapine has been reported to decrease the suicide risk among patients unresponsive to traditional neuroleptics (3). Unfortunately, relatively little research has been done on late-life schizophrenia. In 1996 Jeste (4) found that only about 6 percent of the schizophrenia studies in current issues of leading psychiatric journals focused on older patients.
This review is part of a larger effort to propose steps to prepare for the upcoming crisis in geriatric mental health care (5). We briefly outline the current state of affairs and make specific recommendations for meeting the challenges related to schizophrenia in late life.
What is late-life schizophrenia?
The phrase "late-life schizophrenia" refers to older patients who first manifested schizophrenia in early adulthood, as well as to those whose symptoms first appeared in later life (6). According to the Epidemiologic Catchment Area (ECA) studies (7), the lifetime prevalence of schizophrenia among people age 65 years and older is only .3 percent, and the one-year prevalence is .2 percent.
We believe that several methodologic aspects of the ECA studies may have caused an underestimation of the prevalence of schizophrenia among the elderly population. These studies used DSM-III criteria (8), which did not permit the diagnosis of late-onset schizophrenia and did not include negative symptoms, and they undersampled areas with higher rates of mentally ill elderly persons such as public housing (9). The reliance on retrospective self-reports in the ECA studies also has obvious limitations for older patients with schizophrenia. Thus the true current prevalence of schizophrenia in the elderly population is unknown, but it is probably higher than the ECA figures suggest.
Early-onset schizophrenia
Kraepelin's original conception of dementia praecox was that this disorder was typified by onset in adolescence or young adulthood, with a progressive decline in functioning thereafter (10). Consistent with this view, Davidson and associates (11) reported that more than 60 percent of their sample of chronically institutionalized patients with schizophrenia had diagnosable dementia. However, chronic institutionalization is atypical for most elderly patients with schizophrenia and is experienced by only the most severely ill sector of the population with schizophrenia (12). The decline pictured by Kraepelin appears to characterize the outcome for about 20 percent of patients, while another 20 to 30 percent experience marked improvement or even recovery (13,14,15).
A related issue is the notion of "schizophrenic burnout." It involves a deficit state, with a disappearance of positive symptoms, such as delusions and hallucinations, and an increase in negative symptoms, such as social withdrawal, affective flattening, and avolition. This pattern may describe the course seen in a small minority of patients, but a majority of older patients with schizophrenia continue to have both positive and negative symptoms, and another minority have substantial improvement in both types of symptoms (16,17,18).
The reasons for the recovery seen in some patients in later life are not fully clear. One possibility is changing role expectations—patients who were unable to meet the challenges of young adulthood may have less difficulty meeting role expectations associated with later life, which are typically less challenging. However, we do not believe that this is the main reason for recovery. Neurobiological changes associated with later life that may foster a decrease in psychotic symptoms have been documented; an example is reduction in dopamine activity (19).
The rates of full remission remain uncertain, but there are clear examples of people with schizophrenia who show remarkable recovery after many years of chronic dysfunction. A recently publicized example of recovery is that of John Nash, a Nobel-prize-winning mathematician who developed schizophrenia in his late twenties (18). Dr. Nash's symptoms remitted after decades of severe illness, whereupon he returned to a productive academic career in mathematics.
Patient characteristics that are associated with better outcome include good premorbid adjustment, acute onset of symptoms, short duration of an ongoing episode, and a paucity of negative symptoms (20,21). According to Wyatt (22), early intervention with antipsychotic medications during patients' first psychotic episode may also lead to a better long-term outcome.
Late-onset schizophrenia
The historical tendency to view schizophrenia as having an onset restricted to adolescence or young adulthood was formalized in criteria put forth by Feighner and colleagues (23) and in DSM-III criteria (8), which did not permit diagnosis of schizophrenia if symptoms developed after age 40 or 45, respectively. However, a number of reports challenged this notion (24,25,26,27,28). DSM-III-R (29) permitted diagnosis of schizophrenia late-onset type after age 45, and DSM-IV (30) includes no age-of-onset restriction for diagnosis of schizophrenia.
It has been suggested that late-onset schizophrenia is a neurodegenerative condition (31), results from acquired brain lesions (32), or is secondary to sensory deficits and interpersonal isolation (33,34,35). Such theories suggest that patients with late-onset schizophrenia have relatively normal brain and psychosocial functioning before the onset of these triggering changes. Our studies challenge these views.
In investigations conducted at the Clinical Research Center for the Study of Late-Life Psychoses at the University of California, San Diego, patients with late-onset schizophrenia (those whose age at onset of schizophrenia was 45 years or older) were compared with patients of a similar age who had earlier onset of schizophrenia (16). Similarities between the groups included the severity of positive symptoms, chronicity of course, level of uncorrected sensory impairment, family history of schizophrenia, early childhood maladjustment, increased mortality relative to the general population, qualitative response to neuroleptic medications, overall pattern of neurocognitive impairment, and presence or absence of gross structural brain abnormalities seen via neuroimaging. Similar to early-onset patients, patients with late-onset schizophrenia also had an elevated number of minor physical anomalies compared with normal subjects, suggesting subtle aberrations in their early development (36).
Several differences between early- and late-onset patients were also observed in these studies (16). Patients with late-onset schizophrenia were more likely to be women and to have the paranoid subtype of the disorder. They had less severe negative symptoms, better premorbid functioning in early adulthood, and less impairment in the specific neurocognitive areas of learning and abstraction or cognitive flexibility, and they required lower dosages of neuroleptic medications for management of their psychotic symptoms. Quantitative analyses of MRI scans in a subsample of patients showed larger thalami in the late-onset group than in the early-onset group (37).
The similarities observed between patients with early- and late-onset schizophrenia suggest that the latter is "true" schizophrenia, in that the two groups were similar in terms of apparent genetic risk, positive symptoms, treatment response, and course. On the other hand, the differences between these groups suggest that neurobiologic differences might mediate the onset of schizophrenic symptoms (38,39,40). Elucidation of such mediating factors may suggest novel intervention or prevention strategies.
The cost of schizophrenia
The lifetime prevalence of schizophrenia across all age groups is only about 1 percent, yet it accounts for the largest proportion of mental health care expenditures (41). It has been estimated that the direct and indirect costs of schizophrenia to the U.S. economy in 1991 alone totaled approximately $65 billion (42). The cost of schizophrenia in elderly patients is at least as high as that incurred by patients in their late teens and 20s (43).
The impact of an aging population on the national health budget can be seen in figures for 1987: 57.9 percent of public health care expenditures were for persons age 65 and above (1), but this age group represented less than 13 percent of the population (44). During the 21st century a dramatic increase in geriatric mental health care costs can be expected. It will occur in parallel with an expansion in general health care expenditures due to the aging population.
In addition to the monetary impact, late-life schizophrenia can have an adverse impact on the quality of life of patients and their families. In one study older patients with schizophrenia were found to have a significantly lower quality of well-being than normal comparison subjects (45). In fact, these patients' scores were slightly worse than those of ambulatory AIDS patients.
Treatment
Conventional neuroleptic agents are effective in managing the positive symptoms of many patients, but chronic use is associated with a risk of motor system side effects such as tardive dyskinesia (46). The cumulative annual incidence of tardive dyskinesia among older outpatients treated with low dosages of conventional antipsychotic medications is 29 percent (46), which is about six times that reported for younger adults (47).
Studies involving predominantly younger, physically healthy patients with schizophrenia suggest that the newer atypical antipsychotic medications (the serotonin- and dopamine-blocking antipsychotics) are somewhat more effective than traditional neuroleptics in treating the negative symptoms of schizophrenia while being associated with a lower risk of extrapyramidal symptoms and perhaps tardive dyskinesia (48,49,50,51). On the other hand, large-scale studies evaluating the relative effectiveness and safety of these newer atypical antipsychotics for older patients with schizophrenia are lacking.
Another potential barrier to the use of atypical antipsychotic medications by elderly patients is their cost compared with traditional neuroleptics (52). Pharmacoeconomic analyses involving primarily younger patients suggest that use of atypical antipsychotic medications may be associated with a reduction in the total dollar cost of the disorder, but, again, data are lacking to evaluate the overall cost-benefit ratio of using these medications with older patients (53,54).
The expected state of affairs in 2011
Current trends suggest a possibility of two scenarios for older patients with schizophrenia in 2011, when the first members of the baby-boom generation turn 65.
The dream scenario
Development of better antipsychotic compounds with improved efficacy and side effect profiles will reduce the need for costly inpatient treatment. Treatment advances, including refinement of psychotherapeutic, nonpharmacologic interventions, will facilitate an age-appropriate level of normal daily functioning as well as an improved quality of life for both patients and their caregivers. Improved access to health care and to the necessary community support services along with reduced social stigma will enable patients to join the mainstream of society in a productive fashion.
The nightmare scenario
In the absence of more effective, safer, and affordable treatments, noncompliance with treatment will continue to be a problem. The result will be an unacceptably high relapse rate, with a need for institutionalization. Meanwhile, managed care companies may make it harder to hospitalize patients. A continued lack of insurance coverage for mental illnesses and further erosion of Medicare will lead to a decrease in the number of older persons with schizophrenia in the health care system. Unfortunately, this decrease will be achieved through increased mortality and perhaps an increase in patients in the criminal justice system (42). Neglect of research into psychotherapeutic and other treatments will foster continued ostracism of elderly persons with schizophrenia from the rest of the society.
Analyzing the challenges
Current actions can largely determine whether the dream or nightmare scenario characterizes the state of affairs in 2011 and beyond. The following discussion is an analysis of the strengths, weaknesses, opportunities, and threats of the situation.
Strengths
Demographic imperative.
The number and proportion of people over age 65 with schizophrenia will increase.
Implications of societal costs.
The dream scenario is not necessarily the more costly scenario. We can spend the money on research and training now or spend more on institutionalization a few years from now.
High potential for success.
The expertise to meet this challenge exists today. Cooperative efforts by the government and the private sector and by mental health professionals are necessary for making significant gains in the understanding and treatment of late-life schizophrenia.
Success of atypical antipsychotics.
The recent advent of atypical antipsychotics with superior therapeutic effects and fewer side effects has been a significant leap forward in the treatment of schizophrenia. A fringe benefit of this development has been the pharmaceutical industry's increasing interest in antipsychotics. Neuroleptics have not traditionally yielded large profit margins for drug companies, so they were reluctant to spend research dollars on their refinement. The success of atypical antipsychotics has fostered a positive mindset within the pharmaceutical industry toward developing new and better antipsychotic medications.
Survivors.
Elderly patients with schizophrenia can be viewed as survivors. In this light they can teach the general community much about coping with the challenges presented by a chronic illness.
Weaknesses
Double social stigma.
A double social stigma exists in relation to schizophrenia and aging. Lack of a political voice in this patient group and a bias in our society toward youth and health result in societal neglect of the needs of aging people with schizophrenia. Ignorance about the problem extends to many health care providers, mental health care workers, researchers, and public policy makers (4,55).
Lack of clinical data.
Pessimistic attitudes.
Increased substance abuse.
In the future cohort of elderly people, including those with schizophrenia, more people are likely to have a history of substance abuse (57).
Research difficulties.
Conducting research among older persons with schizophrenia is often challenging because of cognitive impairment, sensory deficits, medical comorbidity, polypharmacy, biological and psychosocial heterogeneity, and a frequent lack of caregivers. Also, the potential impact of this disorder on decision making and other cognitive skills, particularly in an age group at risk for cognitive decline, complicates ethical issues regarding informed consent (58,59).
Opportunities
Collaboration.
We can produce a unique model of collaboration among advocates for mental health and aging, including scientists, professional organizations, government agencies such as the National Institutes of Health and the Department of Veterans Affairs, advocacy groups for the mentally ill and elderly populations such as the National Alliance for the Mentally Ill and the American Association of Retired Persons, the pharmaceutical industry, private foundations, and others.
Prevention.
The means for primary prevention of schizophrenia are not on the immediate horizon, but much may be learned about factors associated with delayed onset and remission of the illness in old age.
Advances.
Threats
Competition for funds.
An increasing number of special-interest groups are competing aggressively for dollars in an era when politicians are hesitant to be seen as increasing public expenditures.
Lack of collaboration.
There has been a lack of sufficient collaboration among many of the groups that need to work together for the necessary initiatives.
The pervasiveness of traditional ideas.
The influence of traditional thinking about schizophrenia remains pervasive. For example, the Kraepelinian notion of dementia praecox retards efforts for rehabilitation in late-life schizophrenia.
Specific goals and suggested strategies
Goals
Four specific goals can be identified.
• In the short term we should attempt to increase the number of older people with schizophrenia in the population by decreasing medical comorbidity and mortality among younger patients and improving patients' access to health care.
• We should continue to seek to improve our understanding of the neurobiological and psychosocial factors underlying late-life schizophrenia, as well as of the health care and social service needs of such patients.
• We should develop more effective and safer pharmacologic, psychosocial, and cognitive-behavioral treatments.
• Rehabilitation efforts for older people with schizophrenia should be expanded and improved, with better social support services and greater help for patients' caregivers.
Strategies
Several steps will be necessary to meet the above goals, including development of age-appropriate diagnostic criteria, expansion of the research infrastructure to explore the interaction of schizophrenic neuropathology and psychosocial deficits with the normative aging changes, and translation of such research into clinical practice and public policy. Specific strategies to foster the occurrence of these steps include:
• A consortium for studies of older adults with schizophrenia should be formed. Pooling resources will decrease the cost of research and make the collection and dispersion of knowledge obtained more efficient.
• Greater emphasis should be placed on multicenter cooperative studies of treatment effectiveness, particularly research that directly translates into clinical care of elderly patients (62).
• Interdisciplinary collaboration among researchers, clinicians, government and industry representatives, and advocacy groups for patients and elderly persons should be encouraged.
Conclusions
The challenges presented by the upcoming increase in the number and proportion of older patients will force us to pay closer attention to the longitudinal course of schizophrenia and the interaction of neurocognitive deficits, psychiatric symptoms, and their treatment with the psychosocial and physical changes associated with normal aging. This challenge may serve as a catalyst in turning the field and our society away from the myopic and pessimistic perspective that has characterized much of the research and thinking about late-life schizophrenia.
Research focused on late-onset schizophrenia may provide unique insights into the factors differentiating vulnerability to schizophrenia from its phenotypic expression. For example, involvement of the thalamus in the expression of schizophrenic symptoms has been suspected for at least 40 years (63), but its precise role remains unclear. Recent findings of larger thalamic volume among patients with late-onset schizophrenia (37) could reflect a protective factor (responsible for the later onset), a pathological factor (responsible for a particular form of schizophrenic vulnerability), or an epiphenomenon of neuroleptic treatment. Documentation of any of these possibilities may provide important insights into the neurobiology of schizophrenia and its treatment. Similarly, the higher prevalence of women among those with late-onset schizophrenia has generated recent interest in the possibility of estrogen replacement as an alternative form of antipsychotic therapy for older women (64).
If the current state of affairs continues, older patients with schizophrenia will continue to have high comorbidity and mortality and may require institutionalization at a considerable financial and emotional cost. By cooperating and uniting our efforts to understand schizophrenia and its treatment in late life, as well as by using our combined political muscle to ensure that the needed changes are made in the allocation of research dollars and mental health coverage, a greater number of persons with schizophrenia will live longer and more productive lives.
Acknowledgments
This work was partly supported by grants K07-MH-0145, MH-43693, MH-49671, MH-45131, and MH-42522 from the National Institute of Mental Health and by the Department of Veterans Affairs.
Footnote
The authors are affiliated with the department of psychiatry at the University of California, San Diego. Ms. Heaton is also with the department of psychology at San Diego State University. Dr. Jeste is also with the psychiatry service of the San Diego Veterans Affairs Medical Center. Send correspondence to Dr. Palmer at the Geriatric Psychiatry Intervention Research Center (116A-1), Veterans Affairs San Diego Healthcare System, 3350 La Jolla Village Drive, San Diego, California 92161 (e-mail, [email protected]). This paper is part of a special section on meeting the mental health needs of the growing population of elderly persons.
References
1.
Hobbs FB, Damon BL (eds):65+ in the United States. Washington DC, US Bureau of the Census, 1996
2.
Caldwell CB, Gottesman II: Schizophrenics kill themselves too: a review of risk factors for suicide. Schizophrenia Bulletin 16:571-589, 1990
3.
Meltzer HY: Suicide in schizophrenia: risk factors and clozapine treatment. Journal of Clinical Psychiatry 59(suppl 3):15-20, 1998
4.
Jeste DV: Growing disparity between need and reality: research in geriatric psychiatry. Current Opinion in Psychiatry 9:279-280, 1996
5.
Jeste DV, Alexopoulous GS, Bartels SJ, et al: Consensus statement on the upcoming crisis in geriatric mental health: research agenda for the next two decades. Archives of General Psychiatry, in press
6.
Harris MJ, Jeste DV: Late-onset schizophrenia: an overview. Schizophrenia Bulletin 14:39-55, 1988
7.
Robins LN, Regier DA (eds): Psychiatric Disorders in America: The Epidemiologic Catchment Area Study. New York, Free Press, 1991
8.
Diagnostic and Statistical Manual of Mental Disorders, 3rd ed. Washington, DC, American Psychiatric Association, 1980
9.
Rabins PV, Black B, German P, et al: The prevalence of psychiatric disorders in elderly residents of public housing. Journal of Gerontology: Medical Sciences 51A:M319-324, 1996
10.
Kraepelin: Dementia Praecox and Paraphrenia, 1919. Translated by Barclay RM. Huntington, NY, Krieger, 1971
11.
Davidson M, Harvey PD, Powchik P, et al: Severity of symptoms in chronically institutionalized geriatric schizophrenic patients. American Journal of Psychiatry 152:197-207, 1995
12.
Cohen CI: Outcome of schizophrenia into later life: an overview. Gerontologist 30:790-797, 1990
13.
Bleuler M: The Schizophrenic Disorders: Long-Term Patient and Family Studies. Translated by Clemens SM. New Haven, Conn, Yale University Press, 1978
14.
Ciompi L: Catamnestic long-term study on the course of life and aging of schizophrenics. Schizophrenia Bulletin 6:606-618, 1980
15.
Harding CM, Brooks GW, Ashikaga T, et al: The Vermont longitudinal study: II. long-term outcome of subjects who once met the criteria for DSM-III schizophrenia. American Journal of Psychiatry 144:727-735, 1987
16.
Jeste DV, Symonds LL, Harris MJ, et al: Non-dementia non-praecox dementia praecox? Late-onset schizophrenia. American Journal of Geriatric Psychiatry 5:302-317, 1997
17.
Gross G, Huber G, Schuttler R: Long-term course of Schneiderian schizophrenia, in Schizoaffective Psychoses. Edited by Marneros A, Tsuang MT. Berlin, Springer-Verlag, 1986
18.
Nasar SA: A Beautiful Mind. New York, Simon & Schuster, 1998
19.
Arranz B, Blennow K, Ekman R, et al: Brain monoaminergic and neuropeptidergic variations in human aging. Journal of Neural Transmission 103:101-115, 1996
20.
Ram R, Bromet EJ, Eaton WW, et al: The natural course of schizophrenia: a review of first-admission studies. Schizophrenia Bulletin 18:185-207, 1992
21.
Mental Disorders: Glossary and Guide to Their Classification in Accordance With the Ninth Revision of the International Classification of Diseases. Geneva, World Health Organization, 1978
22.
Wyatt RJ: Neuroleptics and the natural course of schizophrenia. Schizophrenia Bulletin 17:325-351, 1991
23.
Feighner JP, Robins E, Guze SB, et al: Diagnostic criteria for use in psychiatric research. Archives of General Psychiatry 26:57-63, 1972
24.
Fish F: Senile schizophrenia. Journal of Mental Science 106:938-946, 1960
25.
Rabins P, Pauker S, Thomas J: Can schizophrenia begin after age 44? Comprehensive Psychiatry 25:290-293, 1984
26.
Gold DD Jr: Late age of onset schizophrenia: present but unaccounted for. Comprehensive Psychiatry 25:225-237, 1984
27.
Essa M: Late-onset schizophrenia (ltr). American Journal of Psychiatry 139:1528, 1982
28.
Harris MJ, Cullum CM, Jeste DV: Clinical presentation of late-onset schizophrenia. Journal of Clinical Psychiatry 49:356-360, 1988
29.
Diagnostic and Statistical Manual of Mental Disorders, 3rd ed, rev. Washington, DC, American Psychiatric Association, 1987
30.
Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC, American Psychiatric Association, 1994
31.
Murray RM, O'Callaghan E, Castle DJ, et al: A neurodevelopmental approach to the classification of schizophrenia. Schizophrenia Bulletin 18:319-332, 1992
32.
Miller BL, Lesser IM, Boone KB, et al: Brain lesions and cognitive function in late-life psychosis. British Journal of Psychiatry 158:76-82, 1991
33.
Roth M: Interaction of genetic and environmental factors in the causation of schizophrenia, in Schizophrenia: Somatic Aspects. Edited by Richter D. New York, Pergamon, 1957
34.
Cooper AF, Curry AR, Kay DWK, et al: Hearing loss in paranoid and affective psychoses of the elderly. Lancet 2:851-854, 1974
35.
Varner RV, Gaitz CM: Schizophrenic and paranoid disorders in the aged. Psychiatric Clinics of North America 5:107-118, 1982
36.
Lohr J, Alder M, Flynn K, et al: Minor physical anomalies in older patients with late-onset schizophrenia, early-onset schizophrenia, depression, and Alzheimer's disease. American Journal of Geriatric Psychiatry 5:318-323, 1997
37.
Corey-Bloom J, Jernigan T, Archibald S, et al: Quantitative magnetic resonance imaging in late-life schizophrenia. American Journal of Psychiatry 152:447-449, 1995
38.
DeLisi LE: The significance of age of onset for schizophrenia. Schizophrenia Bulletin 18:209-215, 1992
39.
Jeste DV, McAdams LA, Palmer BW, et al: Relationship of neuropsychological and MRI measures with age of onset of schizophrenia. Acta Psychiatrica Scandinavica 98:156-164, 1998
40.
Jeste DV, Palmer BW, Harris MJ: Response to Almeida's "Early- versus late-onset schizophrenia: is it time to define the difference?" (ltr) American Journal of Geriatric Psychiatry 6:346-347, 1998
41.
Wasylenki DA: The cost of schizophrenia. Canadian Journal of Psychiatry 39(9 suppl 2):S65-S69, 1994
42.
Wyatt RJ, Henter I, Leary MC, et al: An economic evaluation of schizophrenia, 1991. Social Psychiatry and Psychiatric Epidemiology 30:196-205, 1995
43.
Cuffel BJ, Jeste DV, Halpain M, et al: Treatment costs and use of community mental health services for schizophrenia by age-cohorts. American Journal of Psychiatry 153:870-876, 1996
44.
Population Projections of the United States by Age, Sex, Race, and Hispanic Origin:1995 to 2050. Washington, DC, US Bureau of the Census, 1996
45.
Patterson TL, Kaplan RM, Grant I, et al: Quality of well-being in late-life psychosis. Psychiatry Research 63:169-181, 1996
46.
Jeste DV, Rockwell E, Harris MJ, et al: Conventional versus newer antipsychotics in elderly patients. American Journal of Geriatric Psychiatry 7:70-76, 1999
47.
Kane JM, Woerner M, Lieberman J: Tardive dyskinesia: prevalence, incidence, and risk factors. Journal of Clinical Psychopharmacology 8(suppl 4):52S-56S, 1988
48.
Kane JM, Honigfeld G, Singer J, et al: Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Archives of General Psychiatry 45:789-796, 1988
49.
Marder SR, Meibach RC: Risperidone in the treatment of schizophrenia. American Journal of Psychiatry 151:825-835, 1994
50.
Meltzer HY, Fibiger HC: Olanzapine: a new atypical antipsychotic drug. Neuropsychopharmacology 14:83-85, 1996
51.
Small JG, Hirsch SR, Arvanitis LA, et al: Quetiapine in patients with schizophrenia. Archives of General Psychiatry 54:549-557, 1997
52.
Thomas CS, Lewis CS: Which atypical antipsychotic (editl)? British Journal of Psychiatry 172:106-109, 1998
53.
Glazer WM, Johnstone BM: Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia. Journal of Clinical Psychiatry 58(suppl 10):50-54, 1997
54.
Keks NA: Impact of newer antipsychotics on outcomes in schizophrenia. Clinical Therapeutics 19:148-158, 1997
55.
Droge JA, Billig N: Improving practicing physicians' knowledge of geriatric mental health issues. Family Medicine 24:158-160, 1992
56.
Lebowitz BD, Rudorfer MV: Treatment research at the millennium: from efficacy to effectiveness (editl). Journal of Clinical Psychopharmacology 18:1, 1998
57.
Patterson TL, Jeste DV: The potential impact of the baby-boom generation on substance abuse among elderly persons. Psychiatric Services 50:1184-1188, 1999
58.
National Bioethics Advisory Commission: Research involving persons with mental disorders that may affect decision making capacity, 1999. Available at http://bioethics. gov/capacity/TOC.htm
59.
Weiss R: Bioethics group divided over research on mentally ill. Washington Post, Nov 16, 1998, p A6
60.
Rowe JW, Kahn RL: Successful aging. Gerontologist 37:433-440, 1997
61.
Symonds LL, Gladsjo JA, Heaton RK, et al: Patterns of successful neurocognitive aging (abstr). Journal of the International Neuropsychological Society 4:72, 1998
62.
Harris HW, Lebowitz BD: Clinically oriented basic science: emerging opportunities for research in late-life mental disorders (editl). American Journal of Geriatric Psychiatry 5:284-286, 1998
63.
Hill D: Electroencephalogram in schizophrenia, in Schizophrenia: Somatic Aspects. Edited by Richter D. New York, Pergamon, 1957
64.
Lindamer LA, Lohr JB, Harris MJ, et al: Gender, estrogen, and schizophrenia. Psychopharmacology Bulletin 33:221-228, 1997
Information & Authors
Information
Published In
History
Published online: 1 September 1999
Published in print: September 1999
Authors
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
There are no citations for this item
View Options
View options
PDF/ePub
View PDF/ePubGet Access
Login options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).